# New Report Shows Parkinson’s Costs Surpass $82 Billion in US in 2024 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/economic-burden-parkinsons-disease-2024-report/ > **Published:** 2026-04-07T18:09:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:06-04:00 > **Clinical Summary:** Explore the economic burden Parkinsons disease imposes in 2024, highlighting costs and the need for effective treatments including cannabis medicine. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Parkinson’S DiseaseHealthcare EconomicsMovement DisordersCbdAccess Why This Matters The $82 billion economic burden of Parkinson’s disease underscores the urgent need for cost-effective therapeutic interventions, including [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) which shows emerging evidence for motor and non-motor symptoms. This economic reality drives both patient access concerns and the imperative for rigorous [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into all potentially beneficial treatments. Clinical Summary A new report quantifies the total US economic burden of Parkinson’s disease at $82 billion in 2024, exceeding previous projections. This figure encompasses direct medical costs, indirect costs from lost productivity, and caregiver burden. The escalating costs reflect both disease progression in an aging population and the limited effectiveness of current standard therapies in addressing the full spectrum of motor and non-motor Parkinson’s symptoms. Dr. Caplan’s Take “These staggering costs highlight why we cannot afford to ignore any potentially beneficial intervention, including cannabis, which patients are already using for Parkinson’s symptoms often without physician guidance. The economic burden alone justifies more aggressive research investment in cannabinoid therapeutics for movement disorders.” Clinical Perspective 🧠 Clinicians should recognize that economic pressures may drive patients toward [alternative therapies](https://cedclinic.com/medical-cannabis-eligibility-book-appointment/), including cannabis products, regardless of regulatory status. Consider discussing cannabis use openly with Parkinson’s patients, as many are already experimenting with CBD and THC for tremor, sleep, and pain management, often spending significant out-of-pocket funds without medical oversight. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20report%20shows%20Parkinson%27s%20costs%20surpass%20%2482%20billion%20in%20US%20in%202024%20%40drcaplan&url=https%3A//parkinsonsnewstoday.com/news/cost-parkinsons-disease-hits-surpassing-projections/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//parkinsonsnewstoday.com/news/cost-parkinsons-disease-hits-surpassing-projections/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20report%20shows%20Parkinson%27s%20costs%20surpass%20%2482%20billion%20in%20US%20in%202024%20--%20via%20%40drcaplan.bsky.social%20https%3A//parkinsonsnewstoday.com/news/cost-parkinsons-disease-hits-surpassing-projections/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://parkinsonsnewstoday.com/news/cost-parkinsons-disease-hits-surpassing-projections/](https://parkinsonsnewstoday.com/news/cost-parkinsons-disease-hits-surpassing-projections/) Table of Contents - [FAQ](#FAQ)[What is the clinical significance of this cannabis research?](#What_is_the_clinical_significance_of_this_cannabis_research) - [How does CBD relate to Parkinson’s disease treatment?](#How_does_CBD_relate_to_Parkinson8217s_disease_treatment) - [What are the economic implications of cannabis treatments for movement disorders?](#What_are_the_economic_implications_of_cannabis_treatments_for_movement_disorders) - [What types of movement disorders might benefit from cannabis treatment?](#What_types_of_movement_disorders_might_benefit_from_cannabis_treatment) - [Why is this considered an emerging area worth monitoring?](#Why_is_this_considered_an_emerging_area_worth_monitoring) - [Related](#Related) ## FAQ #### What is the clinical significance of this cannabis research? This research has been rated as having “Notable Clinical Interest” with emerging findings worth monitoring closely. It represents developing evidence in cannabis therapeutics that may influence future clinical practice. #### How does CBD relate to Parkinson’s disease treatment? CBD is being studied as a potential therapeutic option for Parkinson’s disease and movement disorders. Research suggests it may help manage certain symptoms associated with these neurological conditions. #### What are the economic implications of cannabis treatments for movement disorders? Healthcare economics research examines the cost-effectiveness of cannabis treatments compared to traditional therapies. This includes analyzing treatment costs, patient outcomes, and overall healthcare system impact. #### What types of movement disorders might benefit from cannabis treatment? [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) focuses primarily on Parkinson’s disease and related movement disorders. Studies investigate how cannabinoids may help with tremors, rigidity, and other motor symptoms. #### Why is this considered an emerging area worth monitoring? This field represents rapidly evolving research with potential policy implications for medical cannabis use. The findings could influence treatment guidelines and regulatory approaches to [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/). [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Types Of Medical Marijuanas – Doctor Recommendations For CBD Gummies And Dosage Learn about different medical marijuana types and expert advice on CBD gummies and proper dosage for various conditions. Explore Medical Marijuana Types CBD Gummies and Alzheimer's: What the Evidence Shows for Cognitive and Behavioral Support Discover current research on CBD gummies and their potential benefits for cognitive and behavioral symptoms in Alzheimer's disease. Read About CBD and Alzheimer's [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) An in-depth look at cannabinoids and how they may support patient care across various medical conditions. [Learn About Cannabinoids](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).